TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL
TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL
复制标题
DOI：
10.1056/nejm198911303212203
复制
发表时间：
1989-11-30
影响因子：
158.5
通讯作者：
GIBAS, A
中科院分区：
文献类型：
--
作者：
DAVIS, GL;BALART, LA;GIBAS, A
慢性丙型肝炎（非甲非乙型肝炎）是一种常见的，经常进行性的病毒性肝病。为了评估抗病毒药物干扰素α治疗的有效性，我们将166例慢性丙型肝炎患者随机分为两组，一组接受300万或100万单位的重组干扰素α治疗，每周3次，持续24周，另一组不接受治疗。在干扰素治疗6个月后，接受300万单位干扰素治疗的患者中，血清丙氨酸氨基转移酶水平正常或接近正常的概率为46%（P < 0.001），接受100万单位干扰素治疗的患者为28%（P < 0.001）。
Chronic hepatitis C (non-A, non-B hepatitis) is a common and often progressive viral liver disease. To assess the efficacy of therapy with the antiviral agent interferon alfa, we randomly assigned 166 patients with chronic hepatitis C to treatment with either 3 million or 1 million units of recombinant interferon alfa three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after six months of interferon therapy was 46 percent in patients treated with 3 million units of interferon (P < 0.001) and 28 percent in those treated with 1 million units (p